Evotec nabs Gates Foundation cash for low-income country COVID-19 antibody work
Seattle-based Just – Evotec Biologics received funding from The Bill & Melinda Gates Foundation to seek out and work on new monoclonal antibody (mAb) drugs to help combat severe forms of COVID-19.
The company, which is the U.S. subsidiary of German biotech-CRO hybrid Evotec, will put the money towards developing antibody treatment candidates that work against severe COVID-19 in vulnerable populations in low and middle income countries, which will likely be left behind in the development race as wealthier countries snap up new treatments and vaccines.